Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV005053934 | SCV005687741 | likely benign | GUCY2D-related recessive retinopathy | 2025-01-30 | reviewed by expert panel | curation | The NM_000180.4(GUCY2D):c.3098C>T (p.Ser1033Leu) variant is predicted to replace the serine at position p.1033 with leucine. This variant is present in gnomAD v.4.1.0 at a GrpMax allele frequency of 0.003423, with 284 alleles / 75032 total alleles in the African/African American population, which is higher than the ClinGen LCA / eoRD VCEP BS1 threshold of >0.0016 (BS1). The computational predictor REVEL gives a score of 0.203, which is below the ClinGen LCA / eoRD VCEP threshold of ≤0.290 and predicts a non-damaging effect on RetGC-1 protein function. In addition, the splicing impact predictor SpliceAI gives a delta score of 0.00, which is below the ClinGen LCA/eoRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4). In summary, this variant meets the criteria to be classified as Likely Benign for GUCY2D-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BS1, BP4. (VCEP specifications version 1.0.0; date of approval 01/22/2025). |
Eurofins Ntd Llc |
RCV000585411 | SCV000226559 | uncertain significance | not provided | 2018-06-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000585411 | SCV000692893 | uncertain significance | not provided | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001083338 | SCV001100631 | likely benign | Cone-rod dystrophy 6; Leber congenital amaurosis 1 | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003982924 | SCV004799872 | likely benign | GUCY2D-related disorder | 2019-05-06 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |